{"id":"de-101-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL3663408","moleculeType":"Small molecule","molecularWeight":"411.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the production of pro-inflammatory cytokines, thereby reducing the severity of ocular inflammation. This is achieved through its mechanism of action, which is not fully elucidated. Further research is needed to fully understand its mechanism of action.","oneSentence":"DE-101 ophthalmic suspension is an anti-inflammatory agent that reduces inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:31.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-infectious uveitis affecting the posterior segment of the eye"}]},"trialDetails":[{"nctId":"NCT01468168","phase":"PHASE2","title":"A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2011-10","conditions":"Dry Eye Disease","enrollment":183},{"nctId":"NCT01118754","phase":"PHASE1, PHASE2","title":"Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2010-04","conditions":"Dry Eye","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DE-101 ophthalmic suspension","genericName":"DE-101 ophthalmic suspension","companyName":"Santen Inc.","companyId":"santen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-101 ophthalmic suspension is an anti-inflammatory agent that reduces inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}